Veerhealth Care Ltd announced it will conduct virtual meetings with analysts and institutional investors on Saturday, October 24, 2026, starting at 3:00 pm.

The company filed an intimation with BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The sessions are scheduled to be held in a one-to-one or group format via virtual mode.

Meeting Details

The interaction is organized in coordination with AKMIL Strategic Advisors. Participants are requested to join the conference call 10 minutes prior to the scheduled time to ensure connectivity.

Management Participation

Senior management will engage directly with the investment community. The following key personnel are listed as speakers for the session:

• Bhavin S. Shah, Managing Director
• Akash Shah, Chief Financial Officer

The company noted that the schedule is subject to changes due to exigencies on the part of the analysts, investors, or the company itself. Discussions will be strictly based on publicly available information.

Regulatory Compliance

This disclosure serves as formal intimation under SEBI listing norms. The schedule is also available on the company's official website. The company emphasized that any forward-looking statements made during the call are subject to risks and uncertainties, including significant changes in the economic environment.

Veerhealth Care has received a confirmed order valued at Rs 454.68 lakh for the supply of face care products. The order was disclosed to the exchange on October 3, 2026.

ORDER DETAILS

The awarding entity is a domestic company whose identity is not disclosed as per confidential terms. The order classification is marked as Significant. The contract terms specify that the supply of face care products must be executed within a period of 45 days. The transaction does not involve related party interests or promoter interest.

ORDER IN FINANCIAL CONTEXT

The Rs 454.68 lakh order value cannot be meaningfully benchmarked against average quarterly revenue, as the pre-computed average quarterly revenue is Rs 0.0 crore based on TTM data. Consequently, the book-to-bill ratio remains mathematically undefined due to zero denominator revenue. This disparity highlights that while order inflow is active, revenue recognition has not yet commenced or reported at scale.

COMPANY ORDER TRACK RECORD

Order inflow velocity has accelerated in the latest quarter. Q2FY27 saw total inflows of Rs 1143.54 crore, a sharp increase from Rs 149.05 crore in Q1FY27. The company has now received orders from multiple entity types, including domestic and entities not disclosed as per confidential terms.

ORDER HISTORY

EXECUTION AND REVENUE QUALITY

The company reports zero consolidated revenue, net profit, and operating profit margin for the trailing twelve months. This indicates that existing backlogs are not currently converting to recognized revenue in the audited financials provided.

WORKING CAPITAL AND EXECUTION CAPACITY

Balance sheet and cashflow data are not explicitly provided in the input for detailed liquidity analysis. With zero operating cashflow and zero revenue, the company's ability to fund working capital for the existing backlog depends entirely on external financing or promoter support. The absence of reported liabilities or equity figures prevents a precise current ratio assessment, but the lack of revenue generation poses a fundamental working capital constraint until orders begin converting to billings.

WHAT TO WATCH

• Execution rate: Quarterly revenue run-rate vs total backlog is currently zero; watch for the first instance of revenue recognition to validate execution capability.
• Margin quality: OPM trajectory on new orders vs historical average is unobservable; initial revenue filings will reveal whether these contracts carry healthy margins.
• Client concentration: A significant portion of the order book comes from entities listed as "Not disclosed as per confidential terms," making it difficult to assess true client concentration risk beyond the named partners.
• Revenue recognition lag: The gap between Rs 1143.54 crore in recent order inflows and Rs 0.0 crore in TTM revenue requires monitoring to ensure orders are translating into billable milestones.
• Entity diversity: Veerhealth Care has now received orders from domestic and undisclosed counterparties across the last two fiscal quarters.

KEY OBSERVATIONS

• Valuation check (as of 03 Oct 2026): P/E of 64.4x against ROCE of 5.4%. Valuation is pricing in execution improvement not yet visible in return ratios. (P/E is price-derived and will change; ROCE is from audited financials)
• Backlog signal: Book-to-bill is undefined due to zero TTM revenue. At this level, execution capacity becomes the binding constraint, as the entire order book must be converted to revenue to justify current market expectations.